Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation

Ji,Qing; Di,Yan; He,Xiaoyun; Liu,Qingzhen; Liu,Jian; Li,Weiyan; Zhang,Lidong

doi:10.3892/mmr.2015.4713

Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation

Authors:
- Qing Ji
- Yan Di
- Xiaoyun He
- Qingzhen Liu
- Jian Liu
- Weiyan Li
- Lidong Zhang
View Affiliations

Affiliations: Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, P.R. China
Published online on: December 23, 2015 https://doi.org/10.3892/mmr.2015.4713
Pages: 1914-1922

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Phosphodiesterase 4 (PDE4) is an adenosine cyclic 3,5-monophosphate-specific degradative enzyme, which is closely associated with the inflammatory response. Among its four subtypes (A‑D), it remains unclear which one exerts suppressive effects on inflammation and reduces neuropathic pain. The present study aimed to examine the modulation of neuroinflammation by PDE4 subtypes in the spinal cord of a rat model of L5 spinal nerve ligation (SNL)‑induced neuropathic pain. The expression levels of PDE4A‑D were measured in the lumbar spinal cords of naïve rats. The rats were then divided into seven groups: The sham group (sham surgery + saline), the saline group (SNL + saline), the vehicle group (SNL + Lipofectamine® RNAiMAX), the mismatch small interfering (si)RNA group (SNL + mismatch siRNA), the PDE4A‑siRNA group (SNL + PDE4A‑siRNA), the PDE4B‑siRNA group (SNL + PDE4B‑siRNA) and the PDE4D‑siRNA group (SNL + PDE4D‑siRNA). In order to determine behavioral changes, mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) were recorded. The mRNA and protein expression levels of PDE4s were also detected. Furthermore, the association between behavioral changes and individual subtypes of PDE4 were studied following intrathecal administration of PDE4A, B and D‑specific siRNA. The expression levels of protein kinases, including phosphorylated-extracellular signal-regulated kinases (p‑ERK), and inflammatory cytokines were measured, in order to explore the underlying mechanisms. Subtypes A, B and D, but not C, were detected in the naïve rats. After SNL, both MWT and TWL were reduced. The mRNA and protein expression levels of PDE4A, B and D were significantly upregulated after 2, 4, 6 and 8 days of SNL. Subtype‑specific siRNA significantly suppressed the elevated expression levels; however, only rats treated with PDE4B siRNA exhibited improved MWT and TWL. Further analysis of the PDE4B siRNA-treated rats demonstrated that 8 days after SNL, the intensity of p‑ERK was reduced, the expression levels of CD11b and glial fibrillary acidic protein GFAP were reduced, as well as the expression levels of proinflammatory cytokines such as tumor necrosis factor‑α, interleukin (IL)‑1β and IL‑6. These results suggested that selective inhibition of PDE4B may relieve neuropathic pain, potentially via the suppression of glial activation and the release of cytokines in the spinal cord.

View Figures

View References

1	Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 132:237–251. 2007. View Article : Google Scholar : PubMed/NCBI
2	Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS and Nurmikko T; European Federation of Neurological Societies: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 17:e1113–e1188. 2010. View Article : Google Scholar
3	Gao YJ and Ji RR: Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 7:482–493. 2010. View Article : Google Scholar : PubMed/NCBI
4	Tsuda M, Inoue K and Salter MW: Neuropathic pain and spinal microglia: A big problem from molecules in 'small' glia. Trends Neurosci. 28:101–107. 2005. View Article : Google Scholar : PubMed/NCBI
5	Watkins LR and Maier SF: Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2:973–985. 2003. View Article : Google Scholar : PubMed/NCBI
6	Liou JT, Liu FC, Hsin ST, Yang CY and Lui PW: Inhibition of the cyclic adenosine monophosphate pathway attenuates neuropathic pain and reduces phosphorylation of cyclic adenosine monophosphate response element-binding in the spinal cord after partial sciatic nerve ligation in rats. Anesth Analg. 105:1830–1837. 2007. View Article : Google Scholar : PubMed/NCBI
7	Taskén K and Aandahl EM: Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 84:137–167. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ottonello L, Morone MP, Dapino P and Dallegri F: Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin Exp Immunol. 101:502–506. 1995. View Article : Google Scholar : PubMed/NCBI
9	Pearse DD, Pereira FC, Marcillo AE, Bates ML, Berrocal YA, Filbin MT and Bunge MB: cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 10:610–616. 2004. View Article : Google Scholar : PubMed/NCBI
10	Pryzwansky KB and Madden VJ: Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils. Cell Tissue Res. 312:301–311. 2003. View Article : Google Scholar : PubMed/NCBI
11	Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) super-family: A new target for the development of specific therapeutic agents. Pharmacol Ther. 109:366–398. 2006. View Article : Google Scholar
12	Lynch MJ, Hill EV and Houslay MD: Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr Top Dev Biol. 75:225–259. 2006. View Article : Google Scholar : PubMed/NCBI
13	Gwak YS and Hulsebosch CE: Remote astrocytic and microglial activation modulates neuronal hyperexcitability and below-level neuropathic pain after spinal injury in rat. Neuroscience. 161:895–903. 2009. View Article : Google Scholar : PubMed/NCBI
14	Liu J, Feng X, Yu M, Xie W, Zhao X, Li W, Guan R and Xu J: Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci Lett. 412:268–272. 2007. View Article : Google Scholar
15	Hama A, Broadhead A, Lorrain DS and Sagen J: The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain. J Neurotrauma. 29:600–610. 2012. View Article : Google Scholar
16	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
17	Doré-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, Rose SD, Beaudet N, Behlke MA and Sarret P: Central delivery of Dicer-substrate siRNA: A direct application for pain research. Mol Ther. 16:1331–1339. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zimmerman M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:109–110. 1983. View Article : Google Scholar
19	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
20	Kawamata T, Omote K, Kawamata M, Iwasaki H and Namiki A: Antinociceptive interaction of intrathecal alpha2-adrenergic agonists, tizanidine and clonidine, with lidocaine in rats. Anesthesiology. 87:436–448. 1997. View Article : Google Scholar : PubMed/NCBI
21	Chung JM, Kim HK and Chung K: Segmental spinal nerve ligation model of neuropathic pain. Methods Mol Med. 99:35–45. 2004.PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
23	Zhang GH, Lv MM, Wang S, Chen L, Qian NS, Tang Y, Zhang XD, Ren PC, Gao CJ, Sun XD and Lu LX: Spinal astrocytic activation is involved in a virally-induced rat model of neuropathic pain. PLoS One. 6:e230592011. View Article : Google Scholar : PubMed/NCBI
24	Liu PY, Lu CL, Wang CC, Lee IH, Hsieh JC, Chen CC, Lee HF, Lin HC, Chang FY and Lee SD: Spinal microglia initiate and maintain hyperalgesia in a rat model of chronic pancreatitis. Gastroenterology. 142:165–173. 2012. View Article : Google Scholar
25	Whitaker CM, Beaumont E, Wells MJ, Magnuson DS, Hetman M and Onifer SM: Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci Lett. 438:200–204. 2008. View Article : Google Scholar : PubMed/NCBI
26	Schaal SM, Garg MS, Ghosh M, Lovera L, Lopez M, Patel M, Louro J, Patel S, Tuesta L, Chan WM and Pearse DD: The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury. PLoS One. 7:e436342012. View Article : Google Scholar : PubMed/NCBI
27	Vicini E and Conti M: Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol. 11:839–850. 1997.PubMed/NCBI
28	Hajjhussein H, Suvarna NU, Gremillion C, Chandler LJ and O'Donnell JM: Changes in NMDA receptor-induced cyclic nucleotide synthesis regulate the age-dependent increase in PDE4A expression in primary cortical cultures. Brain Res. 1149:58–68. 2007. View Article : Google Scholar : PubMed/NCBI
29	Sebastiani G, Morissette C, Lagacé C, Boulé M, Ouellette MJ, McLaughlin RW, Lacombe D, Gervais F and Tremblay P: The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. Neurobiol Aging. 7:691–701. 2006. View Article : Google Scholar
30	Reyes-Irisarri E, Sánchez AJ, García-Merino JA and Mengod G: Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol. 66:923–931. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhuang ZY, Gerner P, Woolf CJ and Ji RR: ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 114:149–159. 2005. View Article : Google Scholar : PubMed/NCBI
32	Choi DC, Lee JY, Lim EJ, Baik HH, Oh TH and Yune TY: Inhibition of ROS-induced p38MAPK and ERK activation in microglia by acupuncture relieves neuropathic pain after spinal cord injury in rats. Exp Neurol. 236:268–282. 2012. View Article : Google Scholar : PubMed/NCBI
33	Li W, Li Y, Zhu S, Ji Q, Shu Y, Zhang L and Liu J: Rosuvastatin attenuated the existing morphine tolerance in rats with L5 spinal nerve transection through inhibiting activation of astrocytes and phosphorylation of ERK42/44. Neurosci Lett. 584:314–319. 2015. View Article : Google Scholar
34	Aronoff DM, Canetti C, Serezani CH, Luo M and Peters-Golden M: Cutting edge: Macrophage inhibition by cyclic AMP (cAMP): Differential roles of protein kinase A and exhange protein directly activated by cAMP-1. J Immunol. 174:595–599. 2005. View Article : Google Scholar : PubMed/NCBI
35	Emery AC and Eiden LE: Signaling through the neuropeptide GPCR PAC1, induces neuritogenesis via a single linear cAMP- and ERK-dependent pathway using a novel cAMP sensor. FASEB J. 26:3199–3211. 2012. View Article : Google Scholar : PubMed/NCBI
36	Woo MS, Jang PG, Park JS, Kim WK, Joh TH and Kim HS: Selective modulation of lipopolysaccharide-stimulated cytokine expression and mitogen-activated protein kinase pathways by dibutyryl-cAMP in BV2 microglial cells. Brain Res Mol Brain Res. 113:86–96. 2003. View Article : Google Scholar : PubMed/NCBI
37	Zhao L and Brinton RD: Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: A cAMP response element-binding protein-dependent mechanism. J Neurosci. 24:2226–2235. 2004. View Article : Google Scholar : PubMed/NCBI
38	Liu J, Zhao X, Cao J, Xue Q, Feng X, Liu X, Zhang F and Yu B: Differential roles of PKA and Epac on the production of cytokines in the endotoxin-stimulated primary cultured microglia. J Mol Neurosci. 45:186–193. 2011. View Article : Google Scholar